|Security||GLKQY / Glenmark Pharmaceuticals (006698755)|
Institutional Stock Ownership and Shareholders
Glenmark Pharmaceuticals (OTC:GLKQY) has 0 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
Largest shareholders include
Glenmark Pharmaceuticals (OTC:GLKQY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Related News Stories
Drug firm Glenmark Pharmaceuticals said it has received final nod from the US health regulator for generic Hydrocortisone Valerate cream used for providing relief in inflammation and itching due to various skin conditions.
Drug firm Glenmark Pharmaceuticals Monday said it has received final nod from the US health regulator for generic Hydrocortisone Valerate cream used for providing relief in inflammation and itching due to various skin conditions.
It’s an advertisement that was carried in all leading dailies last week. With the header as ‘Attention’, the notice asks patients with ASR (articular surface replacement) hip implants by DePuy International, a subsidiary of pharma giant Johnson & Johnson (J&J), to follow up with their orthopedic surgeons for evaluation of their hip implants regularly. The notice further says that the government has constituted a central expert committee and state level committee to address concerns and assess the compensation claims of eligible patients in respect of the ASR hip implants.
Glenmark Pharmaceuticals has completed the transfer of its orthopaedic and pain management business, valued at Rs 635 crore, to a new entity incorporated by leading private equity firm True North.
Drug maker Glenmark Pharmaceuticals on September 28 said it is not seeing any adverse effects from plummeting generic drug prices in US market even as it counters commoditisation with new launches and a pipeline of complex and differentiated products.
as of ET